Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061977 | 0.82 | ATM (0.38) | ALDH1A1CYP2A6HSD17B10GAACA1 | |
| SCHEMBL6996306 | 0.76 | GRIN2D (0.40) | ALDH1A1GPR84CA1CA2CA9 | |
| SCHEMBL6991227 | 0.75 | ERN1 (0.36) | ALDH1A1CYP2A6TDP1KMT2ACA1 | |
| SCHEMBL248055 | 0.75 | GPR84 (0.37) | ALDH1A1POLBGPR84KMT2AHSP90AA1 | |
| SCHEMBL13728469 | 0.74 | CYP2A6 (0.48) | ALDH1A1CYP2A6TSHRHSD17B10TDP1 | |
| SCHEMBL14381324 | 0.74 | POLB (0.38) | ALDH1A1CYP2A6TSHRHSD17B10TDP1 | |
| SCHEMBL17509378 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10POLBGAA | |
| Hydrochloric Acid SCHEMBL6435926 | 0.74 | GPR84 (0.36) | GPR84 | |
| SCHEMBL4071402 | 0.72 | F7 (0.33) | CYP2A6POLB | |
| SCHEMBL17981012 | 0.72 | CYP2A6 (0.38) | ALDH1A1CYP2A6HSD17B10TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068985-A1 | 1-(1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-4257625-A1 | HCFO-CONTAINING ISOCYANATE-REACTIVE COMPOSITIONS, RELATED FOAM-FORMING COMPOSITIONS AND FOAMS | Covestro LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230303757-A1 | HCFO-CONTAINING ISOCYANATE-REACTIVE COMPOSITIONS, RELATED FOAM-FORMING COMPOSITIONS AND FOAMS | COVESTRO LLC | 2023-09-28 | — | — | US | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | ALDH1A1 1211/4885CYP2A6 229/4885TSHR 491/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | ALDH1A1 3219/4885CYP2A6 1404/4885TSHR 101/4885 |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ALDH1A1 3632/4885CYP2A6 4078/4885TSHR 2259/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | ALDH1A1 3827/4885CYP2A6 2834/4885TSHR 3284/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | ALDH1A1 1051/4885CYP2A6 207/4885TSHR 387/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | ALDH1A1 3827/4885CYP2A6 2834/4885TSHR 3284/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ALDH1A1 3632/4885CYP2A6 4078/4885TSHR 2259/4885 |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | ALDH1A1 2620/4885CYP2A6 325/4885TSHR 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.